ECTYCELL
LIVE

Serial Number

79081065

Owner

CELLECTIS

Attorney

Jeffrey H. Greger

Filing Date

Oct 2, 2009

Add to watchlist:

No watchlists yet
View on USPTO

ECTYCELL Trademark

Serial Number: 79081065 • Registration: 3939980

ECTYCELL is a trademark filed by CELLECTIS on October 2, 2009. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 42 (Computer & Scientific), Class 45 (Legal & Security Services). The application is currently registered and active.

Owner Contact Info

CELLECTIS (10 trademarks)

102 avenue Gaston Roussel

Entity Type: 99

Trademark Details

Filing Date

October 2, 2009

Registration Date

April 5, 2011

Published for Opposition

January 18, 2011

Cancellation Date

October 3, 2019

Goods & Services

Scientific apparatus and instruments used in the implementation of biochemical analysis and molecular biology techniques, namely, automated biochemical analyzer, automated protein production and protein purification devices, biochemical, biological automated assay devices, nucleic acid break analyzer, devices for protein-nucleic acid interaction analysis; scientific apparatus and instruments for the mapping of all molecules' biological activities; data processing apparatus; multimedia products, namely, blank magnetic, blank optical, blank image and blank sound recording media; software for recording scientific and medical data on an on-line computer database in the field of pharmaceuticals and biotechnology, for simulation and design of biological and chemical products; apparatus and instruments for non-medical diagnosis, namely, computer hardware, microscopes, spectrometers

Pharmaceutical, veterinary and sanitary products, namely, foods, dietetic beverages, and beverages for medical purposes, nutritional supplements for medical use, cultures and preparations of microorganisms for medical, pharmaceutical and veterinary purposes, bacteriological preparations for medical, pharmaceutical and veterinary purposes, medicines for veterinary purposes derived from or validated with stem-cell derived biologicals and for treating genetic diseases including proliferative disorders such as cancer, immunomodulatory disorders such as immunodeficiency and autoimmune syndromes, single gene disorders such as autosomal dominant, autosomal recessive, X-linked dominant, X-linked recessive, Y-linked and Mitochondrial linked diseases, multifactorial and polygenic disorders, infectious diseases including those caused by pathogenic microbial agents, including pathogenic viruses, pathogenic bacteria, fungi, protozoa, multicellular parasites, medicines for human purposes derived from or validated with stem-cell derived biologicals and for treating genetic diseases including proliferative disorders such as cancer, immunomodulatory disorders such as immunodeficiency and autoimmune syndromes, single gene disorders such as autosomal dominant, autosomal recessive, X-linked dominant, X-linked recessive, Y-linked and Mitochondrial linked diseases, multifactorial and polygenic disorders, infectious diseases including those caused by pathogenic microbial agents, including pathogenic viruses, pathogenic bacteria, fungi, protozoa, multicellular parasites, biological preparations for medical, pharmaceutical and veterinary purposes for grafts, cell therapy and regenerative medicine, for treating genetic diseases including proliferative disorders such as cancer, immunomodulatory disorders such as immunodeficiency and autoimmune syndromes, single gene disorders such as autosomal dominant, autosomal recessive, X-linked dominant, X-linked recessive, Y-linked and Mitochondrial linked diseases, multifactorial and polygenic disorders, infectious diseases including those caused by pathogenic microbial agents, including pathogenic viruses, pathogenic bacteria, fungi, protozoa, multicellular parasites, chemical and biochemical preparations for medical, pharmaceutical and veterinary purposes for treating genetic diseases including proliferative disorders such as cancer, immunomodulatory disorders such as immunodeficiency and autoimmune syndromes, single gene disorders such as autosomal dominant, autosomal recessive, X-linked dominant, X-linked recessive, Y-linked and Mitochondrial linked diseases, multifactorial and polygenic disorders, infectious diseases including those caused by pathogenic microbial agents, including pathogenic viruses, pathogenic bacteria, fungi, protozoa, multicellular parasites, chemical-pharmaceutical preparations for treating genetic diseases including proliferative disorders such as cancer, immunomodulatory disorders such as immunodeficiency and autoimmune syndromes, single gene disorders such as autosomal dominant, autosomal recessive, X-linked dominant, X-linked recessive, Y-linked and Mitochondrial linked diseases, multifactorial and polygenic disorders, infectious diseases including those caused by pathogenic microbial agents, including pathogenic viruses, pathogenic bacteria, fungi, protozoa, multicellular parasites, diagnostic preparations for medical purposes

Chemical, biochemical, biotechnological and bacteriological products for use in industry, science, agriculture, horticulture, namely, chemicals used for industrial purposes, polypeptides for in vivo and in vitro genetic engineering, nucleic acid vectors, natural and engineered meganucleases and endonucleases; chemical, biochemical, biotechnological and bacteriological products for use in research and testing laboratories, namely, polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors; chemical, biochemical, biotechnological and bacteriological preparations for scientific purposes namely, bacteriological preparations producing polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors; diagnostic preparations for scientific purposes; proteins being raw materials

Intellectual property licensing; patent licensing

Scientific research and industrial research in the field of genome engineering, protein engineering; scientific research in the field of genetics, medical, pharmaceutical and veterinary research; scientific research in the field of biology, biochemistry, molecular biology, bacteriology; scientific analysis; scientific research and development of biochemical, biological and molecular biology analysis techniques; research and development of new molecules for industrial use, scientific laboratory services, namely, isolation and preparation of stem cells; laboratory services, namely, imaging core lab services; engineering services, particularly technical project planning; computer programming, computer software and multimedia software design and development

Filing History

NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED
Apr 17, 2020 DENC
DEATH OF INTERNATIONAL REGISTRATION
Apr 17, 2020 DETH
CHANGE OF NAME/ADDRESS REC'D FROM IB
May 2, 2019 ADCH
TOTAL INVALIDATION PROCESSED BY THE IB
Sep 14, 2018 INNT
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Jul 19, 2018 INTS
INVALIDATION PROCESSED
Jul 19, 2018 INPC
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Jul 10, 2018 INTR
CANCELLED SECTION 71
Nov 10, 2017 C71T
NEW REPRESENTATIVE AT IB RECEIVED
Mar 27, 2014 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
May 19, 2013 FINO
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 28, 2013 TCCA
FINAL DISPOSITION NOTICE SENT TO IB
Aug 29, 2011 FICS
FINAL DISPOSITION PROCESSED
Aug 29, 2011 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jul 5, 2011 FICR
REGISTERED-PRINCIPAL REGISTER
Apr 5, 2011 R.PR
PUBLISHED FOR OPPOSITION
Jan 18, 2011 PUBO
NOTICE OF PUBLICATION
Dec 29, 2010 NPUB
LAW OFFICE PUBLICATION REVIEW COMPLETED
Dec 13, 2010 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 13, 2010 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 19, 2010 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 19, 2010 CRFA
ASSIGNED TO LIE
Nov 19, 2010 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 4, 2010 TROA
REFUSAL PROCESSED BY IB
Jun 18, 2010 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
May 7, 2010 RFCS
REFUSAL PROCESSED BY MPU
May 7, 2010 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
May 5, 2010 RFCR
NON-FINAL ACTION WRITTEN
May 4, 2010 CNRT
APPLICATION FILING RECEIPT MAILED
Apr 27, 2010 MAFR
ASSIGNED TO EXAMINER
Apr 23, 2010 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 23, 2010 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Apr 22, 2010 REPR